Handelsbanken Fonder Ab Innoviva, Inc. Transaction History

Handelsbanken Fonder Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$12.32 - $16.27 $101,024 - $133,414	8,200 Added 56.65%	22,676 $364,000
Q4 2022 Feb 07, 2023	SELL	$11.8 - $13.78 $70,800 - $82,680	-6,000 Reduced 29.3%	14,476 $192,000
Q3 2022 Oct 27, 2022	BUY	$11.61 - $15.22 $9,288 - $12,176	800 Added 4.07%	20,476 $238,000
Q2 2022 Aug 03, 2022	SELL	$14.32 - $19.88 $14,320 - $19,880	-1,000 Reduced 4.84%	19,676 $290,000
Q2 2021 Aug 03, 2021	BUY	$11.45 - $13.96 $41,220 - $50,256	3,600 Added 21.08%	20,676 $277,000
Q2 2020 Aug 13, 2020	BUY	$11.49 - $15.26 $196,203 - $260,579	17,076 New	17,076 $239,000

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.